Brief Intervention to Reduce Fear of Public Speaking

• Status: Terminated
• Trial end date: 2020-10-30
• Target enrollment: 0
• Participant gender: All

Summary

The study will test the efficacy of propranolol or placebo, administered after retrieval of a previously acquired public speaking fear, in reducing fear and avoidance of public speaking.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York State Psychiatric Institute
• Treatments: Propranolol

Criteria

Inclusion Criteria:

• 18-60 years of age at the time of consent

• Principal Diagnosis of Social Anxiety Disorder, Performance only type

• Has clinically significant fear of public speaking

• Physically healthy

• If female, non-pregnant and not nursing

• Off all psychotropic drug for at least 4 weeks

• A level of understanding sufficient to provide written informed consent to all required study tests and procedures.

Exclusion Criteria:

• History of other serious psychiatric disorder

• Current Major Depressive Disorder

• Presence of developmental disorder or intellectual disability

• SAD patients with SAD not of the performance only type

• Women who are pregnant or nursing

• Current use of psychiatric medication

• Current substance use disorder

• Persons planning to start another treatment during the study period.

• Any significant medical condition that might increase the risk or participation (e.g., seizure disorder, respiratory disorders [e.g., bronchial asthma], cardiovascular disease [e.g., congestive heart failure, heart arrhythmias, sinus bradycardia and greater than first degree block ], low blood pressure [ < 90/60], diabetes, liver or kidney disorders)

• Use of medications that might negatively interact with propranolol (e.g., ACE inhibitors; catecholamine depleting drugs, such as reserpine; calcium channel blockers; digitalis glycosides; haloperidol; chlorpromazine; aluminum hydroxide gel; phenytoin; phenobarbitone; rifampin; antipyrine; lidocaine; cimetidine; theophylline)